text
"['\n1. 요약재무정보\n가. 연결 재무정보\n1) 요약재무정보(연결)\xa0\n(단위 : 원 )\n구 분\n제64기 반기\n제63기\n제62기\n[유동자산]\n27,854,371,626\n22,179,284,235\n32,335,811,726\nㆍ당좌자산\n20,112,841,365\n14,076,873,659\n22,324,638,175\nㆍ재고자산\n7,741,530,261\n8,102,410,576\n10,011,173,551\n[비유동자산]\n55,040,899,517\n49,926,110,781\n51,753,184,638\nㆍ투자자산\n8,288,430,600\n1,758,505,677\n5,803,907,176\nㆍ유형자산\n34,926,750,898\n37,192,300,892\n41,668,859,785\nㆍ무형자산\n1,968,399,115\n2,208,933,367\n2,646,703,007\nㆍ기타비유동자산\n9,857,318,904\n8,766,370,845\n1,633,714,670\n자산총계\n82,895,271,143\n72,105,395,016\n84,088,996,364\n[유동부채]\n20,906,206,568\n11,423,664,047\n14,918,333,308\n[비유동부채]\n7,557,614,190\n8,718,770,938\n6,524,272,722\n부채총계\n28,463,820,758\n20,142,434,985\n21,442,606,030\n[지배기업의 소유주에게 귀속되는 자본]\n54,431,263,291\n51,962,805,680\n64,787,134,464\nㆍ자본금\n59,284,983,000\n50,899,498,000\n114,267,552,000\nㆍ연결자본잉여금\n3,435,078,941\n3,227,318,552\n3,227,318,552\nㆍ연결기타자본항목\n5,526,102,791\n6,039,466,270\n8,630,005,372\nㆍ연결이익잉여금\n(13,814,901,441)\n(8,203,477,142)\n(61,337,741,460)\n[비지배지분]\n187,094\n154,351\n(2,140,744,130)\n자본총계\n54,431,450,385\n51,962,960,031\n62,646,390,334\n매출액\n23,985,762,500\n37,699,312,899\n30,373,353,893\xa0\n영업이익(손실)\n(679,988,408)\n(11,249,275,255)\n(10,123,767,392)\n연결당기순이익(손실)\n(9,455,124,767)\n(11,644,021,627)\n(30,174,299,094)\n지배회사지분 순이익(손실)\n(9,455,164,746)\n(10,880,761,694)\n(19,505,949,555)\n보통주 기본주당순이익(손실)\n(88)\n(107)\n(112)\n보통주 희석주당순이익(손실)\n(88)\n(107)\n(112)\n연결에 포함된 회사수\xa0\xa0 (단위 : 개)\n2\n2\n2\n※ 한국채택국제회계기준 작성기준에 따라 작성되었습니다.\xa0\xa0\n2)재무제표 재작성- 해당 없음 -\n3) 당기에 신규로 연결재무제표에 포함된 종속기업이나 당기 중 연결재무제표의 작성대상에서 제외된 종속기업은 다음과 같습니다.\xa0 \xa0\n회계기준\n제64기\n제63기\n제62기\n한국채택국제회계기준(K-IFRS)적용 시\nORIENT SCIENCE & HEALTHCARE, INC.Orient Bioresource Center Inc\nORIENT SCIENCE & HEALTHCARE, INC.Orient Bioresource Center Inc\nORIENT SCIENCE & HEALTHCARE, INC.Orient Bioresource Center Inc\n4) 연결재무제표 작성 기준- 자세한 사항은 \'3. 연결재무제표 주석\'을 참조 바랍니다.\xa0\n나. 별도 재무정보\n1) 요약 재무정보(별도)\xa0\n(단위 : 원 )\n구 분\n제64기 반기\n제63기\n제62기\n[유동자산]\n24,783,670,689\n20,352,110,481\n33,043,976,531\nㆍ당좌자산\n18,471,662,478\n16,664,473,420\n26,016,424,616\nㆍ재고자산\n3,998,878,650\n3,629,453,520\n6,884,426,799\nㆍ기타유동자산\n2,313,129,561\n58,183,541\n143,125,116\n[비유동자산]\n52,345,398,707\n46,373,942,102\n55,039,362,875\nㆍ투자자산\n16,035,399,275\n9,302,804,619\n5,804,691,806\nㆍ유형자산\n24,484,281,413\n26,095,833,271\n31,137,265,312\nㆍ무형자산\n1,968,399,115\n2,208,933,367\n2,646,703,007\nㆍ기타비유동자산\n9,857,318,904\n8,766,370,845\n15,450,702,750\n자산총계\n77,129,069,396\n66,726,052,583\n88,083,339,406\n[유동부채]\n18,467,259,465\n8,894,879,825\n14,334,056,074\n[비유동부채]\n7,557,614,190\n8,718,770,938\n6,233,963,052\n부채총계\n26,024,873,655\n17,613,650,763\n20,568,019,126\n[자본금]\n59,284,983,000\n50,899,498,000\n114,267,552,000\n[자본잉여금]\n3,435,078,941\n3,227,318,552\n3,227,318,552\n[기타자본항목]\n173,053,395\n173,053,395\n183,069,539\n[이익잉여금]\n(11,788,919,595)\n(5,187,468,127)\n(50,162,619,811)\n자본총계\n51,104,195,741\n49,112,401,820\n67,515,320,280\n종속·관계·공동기업투자주식의 평가방법\n원가법\n원가법\n원가법\n2020년4월부터2020년9월까지\n2019년4월부터2020년3월까지\n2018년4월부터2019년3월까지\n매출액\n16,258,528,316\n30,480,028,297\n26,717,684,075\n영업이익(손실)\n(1,730,958,401)\n(11,006,657,091)\n(7,106,603,047)\n당기순이익(손실)\n(10,383,307,682)\n(19,053,556,015)\n(21,365,618,595)\n보통주 기본주당순이익(손실)\n(97)\n(187)\n(122)\n보통주 희석주당순이익(손실)\n(97)\n(187)\n(122)\n※ 한국채택국제회계기준 작성기준에 따라 작성되었습니다.(별도 기준)\xa0 \xa0\xa0\xa0 \xa0 \xa0 \xa02) 재무정보 이용상의 유의점 (별도재무제표 기준)- 전기에 제출된 사업보고서의 첨부자료 ""5. 재무제표 주석""을 참조바랍니다.\xa0\n']"
